Kenneth Krisko

Partner
kkrisko@cooley.com
Full contact info

I work closely with my clients to understand their business and strategic objectives and to structure and negotiate transactions to meet those objectives.

About Kenneth

Kenneth Krisko's practice focuses on the representation of public and private life sciences companies in a broad range of commercial and corporate finance matters. He advises clients regularly with respect to complex commercial transactions designed to maximize the value of pharmaceutical products and technology assets, including technology licenses and acquisitions, research and development collaborations, distribution and manufacturing agreements, and profit-sharing and co-promotion arrangements.

View full bio

Experience

Immatics Announces Collaboration With Moderna

Immatics Announces Collaboration With Moderna

September 11, 2023

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its strategic collaboration with Moderna.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Stephanie Parker Palmer
Special Counsel, Reston
J. Brian Stalter
Special Counsel, New York
Carly Robinson
Associate, Reston
David D. Suh
Associate
Freddy Yip
Associate, Hong Kong
Jacqueline Grise
Partner, Washington DC
Sharon Connaughton
Special Counsel, Washington DC
Rubin Waranch
Associate, Washington DC
Alexander Israel
Partner in Charge – Brussels, Brussels
Stella Sarma
Special Counsel, Brussels
Jan Lang
Associate, Brussels
Kimberly Nguyen
Special Counsel, Reston
Liza Hadley
Associate, Boston
Aaron Pomeroy
Partner, Colorado
Amanda Pacheco
Associate, Palo Alto
Rachel Thorn
Partner, New York
Matthew Pavao
Partner, Boston

Related Practices & Industries

Life Sciences
Life Sciences Corporate Partnering & Licensing
Antitrust & Competition
Technology Transactions
Tax
Intellectual Property Litigation

Cooley Advises Quell Therapeutics on its Exclusive Treg Collaboration With AstraZeneca

Cooley Advises Quell Therapeutics on its Exclusive Treg Collaboration With AstraZeneca

June 9, 2023

Cooley advised Quell Therapeutics, a leading T-regulatory (Treg) cell therapy biotech company based in London, on its exclusive collaboration with AstraZeneca.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Frances Stocks Allen
Partner, London
Tom Goodman
Partner, London
Jiqiang Lin
Associate, New York
J. Brian Stalter
Special Counsel, New York
Ellen Dewhurst
Associate, London

Related Practices & Industries

Life Sciences
Life Sciences Corporate Partnering & Licensing
Emerging Companies

Poseida Therapeutics Enters Strategic Collaboration and License Agreement With Roche

Poseida Therapeutics Enters Strategic Collaboration and License Agreement With Roche

August 6, 2022

Cooley advised Poseida Therapeutics, a clinical-stage biopharmaceutical company, on its strategic collaboration and license agreement with Roche. Lawyers Ken Krisko, Marya Postner, Bin Wang, Hajra Nashin and Brendan Haberle led the Cooley team advising Poseida. 

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Marya Postner
Partner, Palo Alto
Bin Wang
Special Counsel, Palo Alto
Hajra Nashin
Associate, San Diego
Brendan Haberle
Associate, San Diego
Edmond Lay
Associate, San Diego
Tom Coll
Partner, San Diego
Sharon Connaughton
Special Counsel, Washington DC
Jacqueline Grise
Partner, Washington DC
Amanda Pacheco
Associate, Palo Alto
Jeffrey J. Tolin
Partner, New York
Ivor Elrifi
Partner, New York
Matthew Pavao
Partner, Boston
Rachel Thorn
Partner, New York
Natasha Leskovsek
Of Counsel, Washington DC
Liza Cotter
Associate, Boston
Yasmin Roland
Associate, Brussels
David Navetta
Partner, Colorado
Patrick Van Eecke
Partner, Brussels
Maricel Mojares-Moore
Special Counsel, San Francisco

Related Practices & Industries

Life Sciences Corporate Partnering & Licensing
Life Sciences
Healthcare

Immatics Enters Global Exclusive License Agreement With Bristol Myers Squibb

Immatics Enters Global Exclusive License Agreement With Bristol Myers Squibb

December 22, 2021

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its license, development and commercialization agreement with Bristol Myers Squibb for its TCR bispecific candidate, IMA401. Lawyers Ken Krisko, Carly Robinson, Brian Stalter and Stephanie Palmer led the Cooley team advising Immatics.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Carly Robinson
Associate, Reston
J. Brian Stalter
Special Counsel, New York
Stephanie Parker Palmer
Special Counsel, Reston
Nicollette R. Kirby
Associate, Washington DC
Alexander Israel
Partner in Charge – Brussels, Brussels
Jan Lang
Associate, Brussels
Aaron Pomeroy
Partner, Colorado
Amanda Pacheco
Associate, Palo Alto
Rachel Thorn
Partner, New York
Patrick Van Eecke
Partner, Brussels
Bartholomäus Regenhardt
Associate, Brussels
Stella Sarma
Special Counsel, Brussels
Christine Graham
Special Counsel, London
Hajra Nashin
Associate, San Diego
Douglas Lyles
Senior Research Services & Access Analyst

Related Practices & Industries

Life Sciences
Life Sciences Corporate Partnering & Licensing
Antitrust & Competition
Tax
Arbitration
Cyber/Data/Privacy

Poseida Therapeutics Enters Research Collaboration With Takeda to Develop Novel Gene Therapies

Poseida Therapeutics Enters Research Collaboration With Takeda to Develop Novel Gene Therapies

November 17, 2021

Cooley advised Poseida Therapeutics, a clinical-stage biopharmaceutical company, on its research collaboration and exclusive license agreement with Takeda Pharmaceutical Co. Lawyers Ken Krisko and Brendan Haberle led the Cooley team advising Poseida.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Brendan Haberle
Associate, San Diego
Jacqueline Grise
Partner, Washington DC
Sharon Connaughton
Special Counsel, Washington DC
Edmond Lay
Associate, San Diego
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Life Sciences
Life Sciences Corporate Partnering & Licensing
Mergers & Acquisitions
Antitrust & Competition
Public Companies
Emerging Companies
Tax
View more

Rankings & accolades

Legal 500: Key Lawyer – Healthcare: Life Sciences (2021)

Memberships & affiliations

American Bar Association